Latest Market Expansion News

Chrysos Corporation has confirmed its FY25 financial results, reporting $66.1 million in revenue and $16.1 million EBITDA, while reinforcing its commitment to advancing its PhotonAssay technology for mining analysis.

Tyro Payments Limited reported FY25 results with strong top-line growth and margin expansion, setting a confident outlook for FY26 backed by AI-driven efficiency and an expanded market.

Tyro Payments delivered solid FY25 results with a 10.6% rise in EBITDA and accelerated growth initiatives, including expansion into new $40 billion addressable markets and a pilot banking platform.

Tyro Payments reported modest transaction growth and a 10.6% rise in EBITDA for FY25, while preparing for a CEO change and expanding into new industry verticals.

CleanSpace Holdings Limited reported a 26% increase in revenue to $19.8 million for FY25, alongside a significant reduction in net loss to $478,276. The company’s strategic expansion and innovation efforts underpin its improving financial health and global market presence.

Propel Funeral Partners reported a solid 14.5% increase in statutory profit for FY25, driven by strategic acquisitions despite a slowdown in death volumes. The company also declared a fully franked final dividend of 7.0 cents per share.

Austco Healthcare Limited reported a record $81.4 million in revenue for FY25, driven by organic growth and acquisitions including G&S Technologies. EBITDA jumped 62% to $13 million, reflecting strong operational leverage.

Johns Lyng Group reported a modest 1.8% revenue increase for FY25, driven by strong business-as-usual growth despite a steep decline in catastrophe-related income. The company’s FY26 forecast anticipates continued revenue expansion amid ongoing operational challenges.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.